NATURAL HISTORY PREVENTION OF VIRAL HEPATITIS IN ALASKA NATIVE PEOPLE

阿拉斯加原住民病毒性肝炎的自然史预防

• 批准号: 7646414
• 负责人: Brian James McMahon
• 金额: $ 23.2万
• 依托单位: ALASKA NATIVE TRIBAL HEALTH CONSORTIUM
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-30 至 2013-06-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7646414
• 关键词: NATURAL; HISTORY; PREVENTION; VIRAL; HEPATITIS

DESCRIPTION (provided by applicant): Infections from hepatitis A virus (HAV) and hepatitis B virus (HBV) are significant problems in Alaska Natives. Hepatitis A and B vaccines have been routine immunizations in Alaska Natives since 1984 and 1994, respectively. Hepatitis A vaccine is administered to all children over 1 year of age in the US and catch-up hepatitis A virus (HAV) vaccine programs are employed in several states for all children. Hepatitis B vaccine has been administered to all neonates and children in the US for the past decade and to high risk individuals. In addition, chronic hepatitis B and C infections are significant causes of morbidity and mortality from hepatocellular carcinoma (HCC) and cirrhosis in high risk populations in the US. Alaska Natives have one of the highest rates of chronic HBV infection of any ethnic group in the US and a high rate of morbidity and mortality from hepatitis C infection. Not all persons with chronic hepatitis B or C will develop cirrhosis or HCC and the risk factors for progression are not completely elucidated. Population studies are needed to study risk factors for progression of chronic HBV and HCV. The Liver Disease and Hepatitis Program (LDHP) of the Alaska Native Tribal Health Consortium(ANTHC) working collaboratively with the Arctic Investigations Program (AIP) of the Centers for Disease Control and Prevention (CDC) has cohorts of persons who received hepatitis A and B vaccine as infants, children and adults available to determine long-term protection. In addition, the LDHP has recruited large cohorts of Alaska Natives with chronic hepatitis B or C infection.

描述（由申请人提供）： 肝炎A病毒（HAV）和丙型肝炎病毒（HBV）感染是重大问题 阿拉斯加原住民。丙型肝炎和B疫苗已经是阿拉斯加当地人常规免疫 自1984年和1994年以来。丙型肝炎疫苗均针对1多个儿童。 美国的年龄和追赶肝炎病毒（HAV）疫苗计划已采用 所有儿童的几个州。丙型肝炎疫苗已施用给所有新生儿， 在过去的十年中，美国的儿童和高风险个人。此外，美国肝细胞癌（HCC）（HCC）和美国高风险种群中肝炎的慢性肝炎和C感染是发病率和死亡率的重大原因。阿拉斯加的当地人是美国任何种族的慢性HBV感染率最高，并且乙型肝炎感染的发病率和死亡率很高。并非所有患有慢性乙型肝炎或C的人都会发展出肝硬化或HCC，并且进展的危险因素尚未完全阐明。需要人群研究来研究慢性HBV和HCV进展的危险因素。阿拉斯加土著部落健康联盟（ANTHC）的肝病和肝炎计划（LDHP）与疾病控制和预防疾病控制中心（CDC）的北极研究计划（AIP）合作，有许多接受肝炎和B疫苗作为婴儿，儿童和成人可用的人，可提供肝炎。此外，LDHP还招募了大量患有慢性丙型肝炎或C感染的阿拉斯加当地人。